Abstract:BACKGROUND Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM To elucidate whether clopidogrel is beneficial against DN by using a db / db mouse model. METHODS db/db mice with a higher urinary albumin/creatinine ratio (ACR) relative to age- and sex-matched wild-type control mice were randomly allocated to clopidogrel and vehicle treatment groups. Clopidogrel was administered at doses of 5, 10, and 20 mg/kg by gavage for 12 wk. Body mass, blood glucose level, and urinary creatinine and albumin concentrations in each group were measured before and after the intervention. Renal fibrosis was evaluated using periodic acid-Schiff and Masson's trichrome staining. The renal protein expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and F4/80 was assessed using immunohistochemistry. Urinary TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-6 levels were analyzed using enzyme-linked immunosorbent assay; TNF-α and IL-1β mRNA expression was measured using real-time quantitative polymerase chain reaction. The protein expression of fibronectin (FN) and collagen I was assessed using immunohistochemistry. RESULTS Clopidogrel treatment did not affect the body mass or blood glucose level of the db/db mice; however, it increased bleeding time and reduced urinary ACR in a dose-dependent manner. Immunohistochemical staining revealed an amelioration of renal fibrosis, significantly lower deposition of FN and collagen I, and significantly lower expression of the proinflammatory cytokines TNF-α and IL-1β and lower levels of urinary TNF-α and MCP-1 in the clopidogrel-treated db/db mice ( P < 0.05). Furthermore, clopidogrel significantly reduced macrophage infiltration into the glomeruli of the db/db mice. CONCLUSION Clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db / db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Key Words: Diabetes, Clopidogrel, Inflammation, Fibronectin, Diabetic nephropathy Core Tip: Diabetic nephropathy is the most common microvascular inflammatory disease among the diabetic complications. Previous studies have shown that clopidogrel administration is an effective means of suppressing inflammation in diseases such as acute myocardial infarction, diabetes, and acute ischemic cerebral infarction. In this study, we aimed to determine whether treatment with clopidogrel has a preventive or therapeutic effect in the kidneys of obese, type 2 diabetic db/db mice. In this experiment, we demonstrated that clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db/db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Citation: Li HQ, Liu N, Zheng ZY, Teng HL, Pei J. Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice. World J Diabetes 2022; 13(8): 600-612 URL: https://www.wjgnet.com/1948-9358/full/v13/i8/600.htm DOI: https://dx.doi.org/10.4239/wjd.v13.i8.600

Clopidogrel Resistance in a Murine Model of Diet-Induced Obesity is Mediated by the Interleukin-1 Receptor and Overcome with DT-678.

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients with or Without Diabetes.

Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice

The mechanisms and therapeutic potential of clopidogrel in mitigating diabetic cardiomyopathy in db/db mice

Type 2 Diabetes Mellitus Decreases Systemic Exposure of Clopidogrel Active Metabolite Through Upregulation of P-glycoprotein in Rats.

Article the Mechanisms and Therapeutic Potential of Clopidogrel in Mitigating Diabetic in Db/db Mice

Clopidogrel Ameliorates High-Fat Diet-Induced Hepatic Steatosis in Mice Through Activation of the AMPK Signaling Pathway and Beyond

Enhanced Platelet Response to Clopidogrel in Zucker Diabetic Fatty Rats Due to Impaired Clopidogrel Inactivation by Carboxylesterase 1 and Increased Exposure to Active Metabolite

P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a

Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Interleukin‐10 Does Not Modulate Clopidogrel Platelet Response in Mice

Enhanced Responsiveness of Platelets to Vicagrel in IL‐10‐deficient Mice Through STAT3‐dependent Up‐regulation of the Hydrolase Arylacetamide Deacetylase in the Intestine

Enhanced Metabolic Activation of and Platelet Response to Clopidogrel in T Cell-Deficient Mice Through Induction of Cyp2c and Cyp3a and Inhibition of Ces1.

Impact of Pancreatic β-Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers

Modifying Effect of Diabetes on the Short-Term Effect of Clopidogrel in Patients with Myocardial Infarction

Clopidogrel-mediated P2Y 12 inhibition according to renal function in patients with diabetes mellitus and coronary artery disease

Decreased Plasma Exposure of Clopidogrel Active Metabolite in Rats after Long‐term Treatment with Clopidogrel